Saturday | 11 October, 2008
Genetic Technologies gets tough
GTG to enforce rights to BRCA patents
Additional Resources
Newsletter Subscription
Genetic Technologies (ASX: GTG) will enforce its exclusive rights to perform diagnostic testing of the BRCA1 and BRCA2 breast cancer genes in Australia and New Zealand.
The company has been paying ongoing licence fees to Myriad Genetics for exclusive rights to perform diagnostic testing but has been allowing other service providers to perform BRCA testing for the last five years.
Genetic Technologies said in a statement it was now enforcing those exclusive rights, preventing several laboratories throughout the country from performing the test.
It said it had invested several million dollars in a high-throughput molecular diagnostic laboratory and had reduced turnaround time to four weeks.
More about GENETIC TECHNOLOGIES, Myriad Genetics
Australian Life Scientist Member Login
IOGEAR Gears Up in Australia 2008-10-09 20:18:00+10
ACRONIS NAMES INDUSTRY VETERAN JASON DONAHUE AS CEO 2008-10-09 09:37:00+10
Multimedia Technology signs exclusive National distribution agreement with Freecom 2008-10-07 14:30:00+10
WD Unveils Affordable, High-Capacity Network Storage For Small Offices And Homes 2008-10-07 11:40:00+10
Multimedia Technology & EVERKI sign exclusive distribution agreement. 2008-10-06 14:34:00+10
Sponsored Links
Subscribe to Australian Life Scientist
Australian Life Scientist is Australia's leading magazine for the life sciences sector. ALS is available free of charge to qualified persons working in the life sciences - register now for your free subscription.
